Early use of asciminib for new CML patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with CML in the last 3 months.
- You must have the specific BCR::ABL1 gene mutation (e13a2 or e14a2).
- You must have taken TKI therapy for 30 days or less, but other treatments like hydroxyurea are allowed.
- You must be generally active and able to care for yourself (ECOG score 0-2).
- Your liver, kidneys, and pancreas must be working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This study looks at how well asciminib works in real-world patients with chronic myeloid leukemia who have already tried at least one other treatment. It aims to see how effective and safe it is in everyday practice.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This study looks at how safe and effective asciminib is for young adults with chronic myeloid leukemia (CML) in the Gulf region. It uses existing medical records to gather information, so no extra visits are needed.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
Hear when a new CML, Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.